Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan

Treatment of latent tuberculosis (TB) infection (LTBI) effectively prevents its progression to active TB. However, long treatment duration and drug-related hepatotoxicity limit the effectiveness of the 9-month daily isoniazid (9H). Data on the 3-month weekly rifapentine plus isoniazid (3  HP) in Asian populations are currently unavailable. We prospectively randomized the LTBI contacts aged ≥12 years with positive tuberculin skin test into 9H and 3 HP groups in four hospitals between January 2014 and May 2016 in Taiwan.

Source: Tuberculosis - June 7, 2018 Category: Respiratory Medicine Authors: Hsin-Yun Sun, Yi-Wen Huang, Wei-Chang Huang, Lih-Yu Chang, Pei-Chun Chan, Yu-Chung Chuang, Sheng-Yuan Ruan, Jann-Yuan Wang, Jann-Tay Wang Tags: Drug Discovery and Resistance Source Type: research